EU/3/06/385

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in December 2008 on request of the sponsor.

On 25 July 2006, orphan designation (EU/3/06/385) was granted by the European Commission to VASTox Plc, United Kingdom, for 2-(4-(diethylamino) phenyl)-6-methyl-2H-benzo[d][1,2,3] triazol-5-amine for the treatment of Duchenne muscular dystrophy.

Key facts

Active substance
2-(4-(Diethylamino) phenyl)-6-methyl-2H-benzo[d][1,2,3] triazol-5-amine
Disease / condition
Treatment of Duchenne muscular dystrophy
Date of decision
25/07/2006
Outcome
Withdrawn
Orphan decision number
EU/3/06/385

Sponsor's contact details

VASTox Plc
91 Milton Park, Abingdon
Oxfordshire, OX14 4RY
United Kingdom
Telephone: +44 12 35 44 39 40
Telefax: +44 12 35 44 39 99

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Association Française contre les Myopathies
    1 Rue de l'Internationale, BP 59
    91002 Evry Cedex
    France
    Telephone: + 33 1 69 47 28 28 / 0810811088
    Telefax: +33 1 60 77 12 16
  • Action Duchenne (formerly PPUK)
    41 West Street
    London
    E11 4JL
    United Kingdom
    Telephone: +44 20 85 56 99 55
    E-mail: info@ppuk.org
  • ASEM Madrid - Asociación Española contra las Enfermedades Neuromusculares
    c/ Fco. Navacerrada, 12, bajo izq
    28028
    Madrid
    Spain
    Telephone: +34 913 613 895
    E-mail: info@asemmadrid.org

How useful was this page?

Add your rating